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Introduction: Tumors of any histological origin can give rise to cutaneous and subcutaneous 
metastases during follow-up. This study aims to evaluate the costs and beneﬁ  ts of electroche-
motherapy (ECT) with the Cliniporator™ vs other currently used methods in the control and 
treatment of cutaneous and subcutaneous advanced neoplasms.
Materials and methods: A cost-effectiveness analysis was carried out on ECT using the 
Cliniporator vs other techniques (radiotherapy, hyperthermia associated with radiotherapy and 
chemotherapy, interferon-alpha, and isolated limb perfusion) for the control and treatment of 
cutaneous and subcutaneous neoplasms. The direct health costs were attributed a value according 
to the Italian National Healthcare System. Resource consumption and clinical outcomes were 
derived from cost survey data collection and literature review.
Results: ECT is cost-effective with an incremental cost effectiveness ratio (ICER) of €1,571.53 
to achieve a further additional response. Radiotherapy and interferon-alpha are the least effective 
strategies. A combination of hyperthermia, chemotherapy, radiotherapy, and interferon-alpha 
treatment are dominated by ECT (more costly and less effective). Isolated limb perfusion is 
the most effective treatment, but is very costly (€18,530.47) because of the use of antiblastic 
drugs (TNFα), with an ICER of €92,717.29.
Conclusions: After sensitivity analysis, the study results conﬁ  rm the favorable cost-effectiveness 
ratio of ECT with the Cliniporator and justify its wider use.
Keywords: Cliniporator, cutaneous and subcutaneous tumors, electrochemotherapy, 
hyperthermia, chemotherapy, radiotherapy, interferon-alpha, isolated limb perfusion, cost-
effectiveness
Introduction
Tumors of any histological origin can give rise to cutaneous and subcutaneous metas-
tases during disease progression; in particular, around 8%–45% of the patients with 
malignant cutaneous melanoma develop metastases. Among these patients, 21.7% 
show satellite and in-transit metastases, 50.2% (regional) lymph node metastases, and 
28.1% distant metastases (Meier et al 2002).
With the exception of distant metastases, surgery is the most widely used thera-
peutic option, followed by radiotherapy, isolated limb perfusion, hyperthermia, and, 
lastly, chemotherapy (Wolf et al 2003).
Some skin metastases are non-resectable because of their location (face, genitals). 
Complications such as bleeding and infections, as well as psychological issues, may 
require less invasive therapeutic options even in the 4th stage of the disease (Balch 
et al 2000).Therapeutics and Clinical Risk Management 2008:4(2) 542
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Besides surgery, radiotherapy also proved to be effective 
in the treatment of metastatic melanomas, with fair percent-
ages of complete response, which increase when radiotherapy 
is associated to hyperthermia (Kim et al 1978).
Hyperthermia can be applied to the whole body, to a body 
region, or locally. Among regional treatments, isolated limb 
perfusion with a variety of cytotoxic agents is often used in 
the treatment of melanoma metastases (Falk et al 2001).
Whereas the above-mentioned therapies have proven 
effective, results with chemotherapy are unsatisfactory and, 
after 20 years, decarbazine is still the most widely used 
cytotoxic agent (Wolf et al 2004).
Recently, electrochemotherapy (ECT) with the Clinipora-
tor™ (IGEA Srl, Carpi [MO], Italy) has been added to clinical 
practice. ECT is an efﬁ  cient local tumor ablation modality 
using electroporation, a physical method that enhances cell 
membrane permeability, and enables non-permeant or poorly 
permeant chemotherapeutic agents to enter cells, greatly 
enhancing their efﬁ  cacy. Exposure of cells to electric pulses 
increases the cytotoxicity of suitable drugs (Sersa et al 1995; 
Mir et al 1998; Jaroszeski et al 2001).
Electrochemotherapy is an elective therapy for melanoma 
metastases; recent studies have proven that it is effective, easy 
to apply, and has a short application time, both for single and 
multiple lesions (Mir et al 2006).
This study aims to develop an economic evaluation of 
ECT and analyze, for the Italian National Healthcare System 
(SSN), the costs and the effectiveness of this innovative thera-
peutic tool in comparison with currently used treatments.
Materials and methods
A cost-effectiveness analysis was carried out on ECT using 
the Cliniporator vs other strategies (radiotherapy, hyper-
thermia in association with radiotherapy and chemotherapy, 
interferon-alpha, and isolated limb perfusion) for the control 
and treatment of cutaneous and subcutaneous neoplasms. The 
direct health costs were attributed a value from the point of 
view of the National Healthcare System. Resources consump-
tion was derived from a literature review.
Cost analysis
No specific reimbursement rate for electroporation has 
been assigned; therefore in current clinical practice ECT 
is assimilated into “tumor ablation and electro-fulguration 
of tumors”. In order to compare more precisely the costs of 
ECT with the costs of the other methods, direct hospital costs, 
and amortization and maintenance costs for the Cliniporator 
were calculated. The costs associated to ECT were assessed 
according to the methods described in the European study 
“Standard operative procedures of the electrochemotherapy: 
instruction for the use of bleomycin or cisplatin administered 
either systemically or locally and electric pulse delivered 
by the Cliniporator by means of invasive or non invasive 
electrodes.” (Mir et al 2006).
Therefore, in order to determine direct hospital costs, six 
therapeutic courses were considered, depending on the kind 
of anesthesia and on the chemotherapy drug administered:
•   Treatment A (Blm): Local anesthesia, intratumoral admin-
istration of bleomycin.
•   Treatment A (CDDP): Local anesthesia, intratumoral 
administration of cisplatin.
•   Treatment B: Local anesthesia, intravenous administration 
of bleomycin.
•   Treatment C (Blm): General anesthesia, intratumoral 
administration of bleomycin.
•   Treatment C (CDDP): General anesthesia, intratumoral 
administration of cisplatin.
•   Treatment D: General anesthesia, intravenous administration 
of bleomycin.
The procedure was considered to last 28 minutes with local 
anesthesia, and 29.5 minutes with general anesthesia, with an 
average use of 1.3 electrodes per procedure (Mir et al 2006).
The costs relating to the staff involved (physicians 
and nurses) and to the required consumables, both for the 
treatment and the procedure, were attributed a value at the 
Azienda Ospedaliera (hospital) of Busto Arsizio (Varese) 
according to national indication of Agenzia Sanitaria 
Nazionale (ASSR 2007). The resulting costs ranged from 
a minimum of €1,229.00 (2nd procedure) to a maximum of 
€1,372.00 (6th procedure); the items that affected costs the 
most were the electrodes, with one electrode costing €900.00, 
including VAT (value added tax). In order to determine 
the amortization and maintenance costs, data given by the 
manufacturing company, IGEA Srl, were considered. The 
annual amortization cost, with a device purchase cost of 
€54,000.00, including VAT, was determined by considering 
an operational lifetime of 8 years and the use of the Clini-
porator on at least 100 patients/year. Thus, the annual cost 
per patient (€67.50) for using the device was determined. 
Similar estimates were carried out for maintenance, based on 
a biannual cost of €6,000.00, VAT included, which resulted 
in an annual cost of around €30.00 per patient.
The manufacturer of the Cliniporator proposes either the 
purchase, or an annual lease of the device for €12,000.00 
including VAT, which includes maintenance. With 100 
patients a year potentially beneﬁ  ting from the treatment Therapeutics and Clinical Risk Management 2008:4(2) 543
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with the Cliniporator, the unit cost would be €120.00 for the 
lease. In the ﬁ  nal valuation of ECT, we considered resorting 
to amortization and maintenance in 50% of the cases, and 
to full service in the rest of the cases. The ﬁ  nal value was 
determined to be just over €1,400.00 (Table 1).
Moreover, our evaluation was in line with the costs 
estimated in the European study (Mir et al 2006), as shown 
in Figure 1.
Cost of radiotherapy treatment (Table 2) was based on 
the “2006 National Tariff Nomenclator” (Health Ministry 
2006) multiplied by numbers of cycles.
Interferon-alpha treatment costs proved to be very 
variable, depending on tumor localization and on the cyto-
toxic agent used. To assess cost of interferon-alpha treatment, 
units of consumed resources were multiplied by the prices 
reported in the ofﬁ  cial Italian price list (Informatore Farma-
ceutico 2007), taking into consideration the daily dosage and 
duration of the treatment (Table 3).
Oncological hyperthermia is a therapy that can be used in 
association with radiotherapy and chemotherapy; by means 
of radiofrequency electromagnetic ﬁ  elds, the tumor tissue is 
heated up to a temperature nearing 43°C or above for about an 
hour; the heat heightens the radiotherapy and chemotherapy 
effects, with a signiﬁ  cant improvement in the lesion control. 
The cost of hyperthermia is €65.80 per procedure, based on the 
Health Ministry 2006, National Tariff Nomenclator; we then 
added the costs of radiotherapy and chemotherapy (Table 4).
Isolated limb perfusion is a therapy used on some cancers 
located in the limbs, combining perfusion with antiblastic 
agents with hyperthermia (between 41°C and 43°C); it is 
a locoregional procedure which enables the release of high 
doses of a cytostatic drug in a limb with in-transit melanoma 
metastases. The technique used is sophisticated and requires 
accurate monitoring of heat dispersion and of limb tem-
perature. Since there is no DRG (Diagnosis Related Groups) 
reimbursement in Italy to cover the costs of this procedure 
(Health Ministry, Hospital DRG tariffs, TUC, 2006), the 
isolated limb perfusion was attributed a value according the 
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Figure 1 Electrochemotherapy: costs of the different therapeutic courses. Derived from Mir et al (2006).
Treatment A (Blm): Local anesthesia, intratumoral administration of bleomycin.
Treatment A (CDDP): Local anesthesia, intratumoral administration of cisplatin.
Treatment B: Local anesthesia, intravenous administration of bleomycin.
Treatment C (Blm): General anesthesia, intratumoral administration of bleomycin.
Treatment C (CDDP): General anesthesia, intratumoral administration of cisplatin.
Treatment D: General anesthesia, intravenous administration of bleomycin.
Table 1 Cost of electrochemotherapy
Costs of all the categories with drugs and electrodes
Treatment A Blm €1,239.33
Treatment A CDDP €1,229.25
Treatment B €1,254.02
Treatment C Blm €1,357.45
Treatment C CDDP €1,347.37
Treatment D €1,372.14
(A) Average cost value of the different 
therapeutic courses
€1,299.93
Amortization cost of the equipment and
manteinance
€97.50
Annual full service €120.00
(B) Average cost value of amortization
and service cost
€108.75
(A+B) Total cost €1,408.68
Note: Treatment A (Blm): Local anesthesia, intratumoral administration of bleomycin.
Treatment A (CDDP): Local anesthesia, intratumoral administration of cisplatin.
Treatment B: Local anesthesia, intravenous administration of bleomycin.
Treatment C (Blm): General anesthesia, intratumoral administration of bleomycin.
Treatment C (CDDP): General anesthesia, intratumoral administration of cisplatin.
Treatment D: General anesthesia, intravenous administration of bleomycin.Therapeutics and Clinical Risk Management 2008:4(2) 544
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Table 2 Cost of radiotherapy treatment
Treatment Code Nr cycles Nr admin.
per cycle
Unit cost Total cost per
treatment 
Electron teletherapy one or opposed ﬁ  elds 92.25.01 5 5 €38.42  €960.50
Simulation and individuation target 92.29.01 1 1 €54.23 €54.23
Dosimetric treatment plan 92.29.04 1 1 €23.86 €23.86
2D treatment planning 92.29.E 1 1 €50.00 €50.00
Start set-up, portal-ﬁ  lms (each ﬁ  lm) 92.29.G 1 1 €35.64 €35.64
Total cost €1,124.23
Health Ministry 2006, National Tariff Nomenclator.
Table 4 Cost of hyperthermia, chemotherapy and radiotherapy
Treatment Sessions or Cycles (mean)  Unit cost Total cost
Hyperthermia 6.13 €65.80 €403.57
Chemotherapy* 6.13 €215.10 €1,318.54
Radiotherapy 5.31 €69.24 €367.84
Hyperthermia+Chemo+Radio Total cost €2,089.96
*Interferone alfa 2b.
Health Ministry 2006, National Tariff Nomenclator.
Table 3 Cost of interferon-alpha treatment
Drug Dose Dose die in U Nr cycles Nr admin. per cycle Unit cost Total cost 
Interferon alfa 2b 20,000,000 U/m2/die 35200000 4 5 €143.40 €2,867.96
10,000,000 U/m2/die 17600000 52 3 €71.70 €11,185.03
Total cost €14,052.98
Informatore Farmaceutico 2007.
survey data on costs presented in Table 5. Table 6 summarizes 
costs of all treatment alternatives.
Effectiveness analysis
The data on effectiveness were derived from a literature 
review. In particular, the effectiveness data on ECT were 
taken from Marty et al (2006). Effectiveness data are sum-
marized in Table 7 and express the beneﬁ  t as a function of 
the achieved tumor response.
The effectiveness data refer to cutaneous and subcu-
taneous metastases; according to the criteria of the WHO 
Handbook for Reporting Results of Cancer Treatment, 
success is evaluated based on the response, which can be: 
complete (CR), partial (PR), objective (OR = CR+PR), 
no change (NC), and progressive disease (PD). As shown 
in Table 7, the success is evaluated on the objective 
response.
Cost-effectiveness analysis
Cost-effectiveness analysis is a systematic method of com-
paring two or more alternative strategies. Their difference 
in cost (incremental cost) is compared with their difference 
in outcomes (incremental effectiveness) by dividing the 
former by the latter. This ratio is known as the incremental 
cost-effectiveness ratio (ICER). After determining the cost 
and effectiveness of each strategy, the programs are com-
pared using the cost-effectiveness ranking algorithm, which 
consists of ranking the alternatives in the order of their costs, 
eliminating those that are dominated by simple dominance. 
In simple dominance, there is another alternative that is both 
more effective and less costly.
Results
Table 8 compares the cost, the effectiveness, the cost per 
response obtained, and the ICER between the different thera-
peutic options. The cost data in the ﬁ  rst column (C) shows 
that radiotherapy proved to be the less costly therapeutic 
alternative in the treatment of cutaneous and subcutaneous 
metastases. Innovative ECT is the second most economical 
choice, followed by the combination of hyperthermia-che-
motherapy-radiotherapy. Interferon-alpha treatment and 
isolated limb perfusion proved to be the costliest options.
In terms of effectiveness (second column [E]), isolated 
limb perfusion is the ﬁ  rst choice, with a very high percentage 
of tumor response, followed by ECT and the combination 
of hyperthermia-chemotherapy-radiotherapy (radiotherapy 
alone is much less effective). Interferon-alpha treatment 
proved to be the least effective choice.Therapeutics and Clinical Risk Management 2008:4(2) 545
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The third column (C/E) expresses an average cost-
effectiveness ratio indicating the average cost per objective 
tumor response to the treatment.
ECT, radiotherapy and the combination of hyperthemia-
chemotherapy-radiotherapy have limited costs, particularly 
in comparison with isolated limb perfusion and Interferon-
alpha treatment.
The sixth column (ICER = ∆C/∆E) shows the ICER 
between the different treatment options.
The amount of €284.45 in the fourth column (∆C) indicates 
the cost difference between ECT and radiotherapy. The 18.1% 
value in the ﬁ  fth column (∆E) represents the difference in 
effectiveness between the above-mentioned therapeutic alter-
natives; in order to achieve a homogeneous comparison, the 
considered effectiveness parameter is the objective response.
ECT proved therefore to be both more costly and more 
effective than radiotherapy; the value of €1,571.53 (ICER) 
represents the cost that the SSN would sustain by using 
ECT instead of radiotherapy to achieve a further additional 
objective response.
In these comparisons, ECT proved to be a dominant strategy 
with respect to the hyperthemia-chemotherapy-radiotherapy 
combination, since it is less costly and more effective.
Furthermore, ECT proved to be a dominant strategy 
with respect to interferon-alpha treatment, being less costly 
(€1,408.68 vs €14,052.98) and deﬁ  nitely more effective (74.1% 
vs 43.6%). If isolated limb perfusion is used instead of the inno-
vative ECT, in order to achieve an additional objective response, 
the ICER value would signiﬁ  cantly increase to €92,717.29.
Sensitivity analysis
A one-way sensitivity analysis was carried out on all the main 
cost parameters of ECT (±10%), and ECT’s effectiveness. 
The cost sensitivity analysis results do not alter the ranking of 
the various options already shown in the preceding tables. In 
particular, it is interesting to report the results of the sensitivity 
analysis of the electrode costs, since this value appeared to be 
the main cost driver in our analysis. If electrode cost declines 
by 10%, the total cost for ECT would be €1,291.68; if elec-
trode cost increases by 10%, the total cost would be €1,525.68 
(Tables 9–10). These new total cost values for ECT fall between 
the cost for radiotherapy and the cost for the combination of 
hyperthemia-chemotherapy-radiotherapy, which perfectly con-
ﬁ  rms the results of the base case (€1,408.68). In Tables 11–12 
we consider a variation between mininum (63.4%) and maxi-
mum (84.8%) ECT effectiveness. Also in this case sensitivity 
analysis conﬁ  rms the results of the base case scenario.
Discussion
The cost-effectiveness results conﬁ  rm the favorable cost-effec-
tiveness ratio for ECT, its applicability, and its ease of use, with 
a cost of €1,901.05 per achieved response. The ICER analysis 
derived the additional cost for SSN in order to obtain a further 
tumor response. Such a value, if ECT is used instead of radio-
therapy, would give an incremental cost of €1,571.53. On the 
other hand, the hyperthermia-chemotherapy-radiotherapy and 
interferon-alpha treatment options were dominated by ECT, 
whereas isolated limb perfusion has an extremely onerous 
cost-effectiveness ratio (€92,717.29) compared with ECT.
The analysis was carried out at standard costs and does 
not take into consideration the potential discretionary power 
of the physician in patient selection in clinical practice. 
Furthermore, our cost evaluation of ECT with the Clinipo-
rator was in line with the values calculated in the European 
study (Mir et al 2006), as shown in Figure 1. The sensitivity 
analysis carried out on the main ECT cost driver, the elec-
trode cost, gave results in line with the base-case scenario; 
the proposed data justify therefore a more widespread use 
Table 5 Cost of isolated limb perfusion
Medical devices and others 
materials
€54.06
Physician’s time (*) €84.59
Nurse’s time (*) €92.59
Drugs (**)
TNF alpha €12,734.24
Melfalan €187.38
Heparin €7.70
Emoderivates €29.00
Total direct costs €13,189.56
Hospitalization (nr. 8.5 die 
in general Surgery Dept.)
€2,252.50
Overhead costs €3,088.41
Total cost per procedure €18,530.47
(*) ASSN 2007 (**) Informatore Farmaceutico 2007.
Source: Cost survey data collection.
Table 6 Summary of costs (all treatment alternatives)
Treatment Cost Source
Radiotherapy €1,124.23 Health Ministry 2006, National 
Tariff Nomenclator
Electrochemotherapy 
(ECT)
€1,408.68 Cost survey data collection
Interferon-alpha 
treatment
€14,052.98 Informatore Farmaceutico 
2007
Hyperthermia+
Chemo+Radio
€2,089.96 Richting et al 2003; Informatore 
Farmaceutico, 2007, Health 
Ministry 2006, National Tariff 
Nomenclator
Isolated limb perfusion €18,530.47 Cost survey data collectionTherapeutics and Clinical Risk Management 2008:4(2) 546
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Table 8 Average cost, effectiveness, and cost-effectiveness ratio per achieved tumor response and incremental cost effectiveness ratio 
(ICER)
C E C/E ∆C ∆E ∆C/∆E
Treatment Cost Effectiveness Average cost
per achieved
response
Delta cost Delta
effectiveness
ICER
Radiotherapy €1,124.23 56.0% €2,007.55 - - -
ECT €1,408.68 74.1% €1,901.05 €284.45 18.1% €1,571.53
Hyperthermia+
Chemo+Radio
€2,089.96 73.3% €2,851.24 - - Dominated
Interferon-alpha treatment €14,052.98 43.6% €32,268.61 - - Dominated
Isolated limb perfusion €18,530.47 92.6% €20,018.51 €17,121.79 18.5% €92,717.29
Table 9 Sensibility analysis: –10% cost of electrodes per procedure
C E C/E ∆C ∆E ∆C/∆E
Treatment Cost Effectiveness Average cost
per achieved
response
Delta cost Delta
effectiveness
ICER
Radiotherapy €1,124.23 56.0% €2,007.55 - - -
ECT €1,291.68 74.1% €1,743.15 €167.45 18.1% €925.12
Hyperthermia+Chemo+Radio €2,089.96 73.3% €2,851.24 - - Dominated
Interferon-alpha treatment €14,052.98 43.6% €32,268.61 - - Dominated
Isolated limb perfusion €18,530.47 92.6% €20,018.51 €17,238.79 18.5% €93,350.87
Table 10 Sensibility analysis: +10% cost of electrodes per procedure
C E C/E ∆C ∆E ∆C/∆E
Treatment Cost Effectiveness Average cost
per achieved
response
Delta cost Delta
effectiveness
ICER
Radiotherapy €1,124.23 56.0% €2,007.55 - - -
ECT €1,525.68 74.1% €2,058.94 €401.45 18.1% €2,217.94
Hyperthermia+
Chemo+Radio
€2,089.96 73.3% €2,851.24 - - Dominated
Interferon-alpha
treatment
€14,052.98 43.6% €32,268.61 - - Dominated
Isolated limb perfusion €18,530.47 92.6% €20,018.51 €17,004.79 18.5% €92,083.72
Table 7 Efﬁ  cacy of the various strategies, based on tumor response
Treatment Effectiveness (OR*) Range (min. – max.) Source
Radiotherapy 56.0% (±10%) Gaudy-Marqueste et al 2006
ECT 74.1% 63.4%–84.8% Marty et al 2006
Hyperthermia+Chemo+Radio 73.3% (±10%) Richtig et al 2003
Interferon-alpha treatment 43.6% 196%–67.5% Hahka-Kemppinen et al 1995; 
Mughal et al 1991; Sersa et al 2000
Isolated limb perfusion 92.6% 87.5%–95.2% Lienard et al 1999; Rossi et al 2004
*Objective responses (the response relates to the treated patients).Therapeutics and Clinical Risk Management 2008:4(2) 547
Electrochemotherapy with the Cliniporator™ for tumors
of ECT with the use of the Cliniporator. The extremely high 
ICER value for isolated limb perfusion justiﬁ  es its limited 
use. Lastly, interferon-alpha treatment proves to be a domi-
nated strategy, being the least effective and most expensive 
of the considered therapies. Currently, ECT is applied mainly 
in the treatment of secondary cutaneous and subcutaneous 
tumors (metastases) of any histological origin, ie, not only 
skin cancers, but also solid tumors, carcinomas, sarcomas, 
and so on that give rise to cutaneous and subcutaneous metas-
tases. Our analysis has some limitations: clinical outcomes, 
for example, were derived from literature review and the 
success was evaluated on the objective response in order to 
compare clinical effectiveness among alternatives. Further 
data on costs and outcomes for ECT need to be collected over 
a longer time frame. Conventional surgery, when applicable, 
appears in clinical practice to be the best choice (Wolf et al 
2003); should surgery prove to be devastating for the patient, 
from the esthetic and functional points of view, ECT is an 
excellent alternative, one reason being the rapid application 
and the scarce side effects (a light muscle contraction on the 
treated site during the delivery of the electric pulses).
Use of ECT with the Cliniporator is preferable to iso-
lated limb perfusion, which has a very high ICER value. 
Other advantages of ECT, not considered in this analysis, are 
the possibility of repeated applications on the same patient if 
new metastases develop, and the possibility of being used 
as an adjuvant to standard therapies. Often, for patients 
with many lesions, lesions in sensitive areas (face, head, 
neck), or large lesions, none of the alternatives to ECT can 
be applied. In these cases, ECT with the Cliniporator is 
not only the therapy of choice, but also the only feasible 
therapy.
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